TXNRD1
Thioredoxin reductase 1, cytoplasmic
As of the edition of 20 October 2026, TXNRD1 (thioredoxin reductase 1, cytoplasmic, UniProt Q16881) has 2 drugs tested at it and 2 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q16881
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 9
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Urinary and reproductive; Lungs and airways; Nervous system; Digestive system
- Registered trials of its drugs
- 165
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Arsenic trioxide | Marketed | Phase 4 | none listed |
| Motexafin gadolinium | Stopped | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Total on the list | 2 |
The other 0 companies at TXNRD1
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at TXNRD1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.